Diagnostic Hybrids Enters Agreement With Microgen

Diagnostic Hybrids Inc. (DHI, Athens, OH, USA) has announced that the company signed a product distribution agreement with Microgen Bioproducts Limited (Camberley, UK) a technology-based diagnostics company. Microgen will be responsible for sales and representation of DHI virology products in Wales, Scotland, Ireland, and England. The distribution agreement is effective immediately and will focus initially on introducing specific respiratory virus detection products in the United Kingdom. This agreement extends the exposure of DHI virology products to a population of 60 million people.

Microgen Bioproducts is an independent, private company that is engaged in the development, manufacture and sale of products used by laboratory professionals to aid in the detection and diagnosis of diseases and organisms which pose a threat to human and animal health. The company supplies infectious disease and food pathogen detection tests. Microgen has expertise and experience in the creation and manufacture of diagnostic tests for enteric pathogens and infectious diseases. They operate a direct sales force in the United Kingdom.

Diagnostic Hybrids is a bioscience firm that develops, manufactures, and markets innovative cell culture products for multiple applications in diagnostic virology and endocrine disease. These products offer laboratory staff a rapid, cost-effective diagnostic solution to an otherwise lengthy and expensive process. They currently sell their products to over 600 customers domestically and throughout North America.

Daniel Deery, Ph.D., managing director of Microgen, predicts that DHI's products will do well in the UK. "Sensitive and innovative tissue cell cultures are becoming difficult for customers in the UK to access locally” explained Dr. Deery, "especially with traditional sources of these cells in the UK closing. We believe DHI's cell culture products are the most sensitive and reliable commercial-grade cell cultures in the world and we are committed to providing our customers immediate access to these products cost-effectively.”

DHI has recently completed preparations for CE Marking of specific products intended for sale in the UK and other countries of Europe. This will allow DHI to freely circulate its products within the European marketplace. In addition, DHI has developed a quality management system that is in compliance with the international standard for medical devices, ISO 13485.



Related Links:
Diagnostic Hybrids
Microgen Bioproducts